ADURO BIOTECH, INC. Contracts & Agreements

Amended and Restated 2015 Equity Incentive Plan (Filed With SEC on August 7, 2023)

Agreement and Plan of Merger, dated as of June 11, 2023, by and among Chinook Therapeutics, Inc., Novartis AG and Cherry Merger Sub Inc (Filed With SEC on June 12, 2023)

Amendment No. 1 to Sales Agreement, dated April 7, 2021, by and between the Registrant and SVB Securities LLC (formerly known as SVB Leerink LLC) and Cantor Fitzgerald & Co., as... (Filed With SEC on November 10, 2022)

Underwriting Agreement by and among Chinook Therapeutics, Inc. and SVB Securities LLC, Cantor Fitzgerald & Co., and William Blair & Company, L.L.C. as Representatives of the... (Filed With SEC on May 25, 2022)

Form of Pre-Funded Warrant (Filed With SEC on May 25, 2022)

SanReno Shareholders Agreement between the Registrant and SanReno Therapeutics Holdings Limited and SanReno Therapeutics (Hong Kong) Limited, a wholly owned subsidiary of SanReno... (Filed With SEC on March 17, 2022)

SanReno License Agreement between the Registrant and SanReno Therapeutics Holdings Limited and SanReno Therapeutics (Hong Kong) Limited, a wholly owned subsidiary of SanReno... (Filed With SEC on March 17, 2022)

Separation Agreement between the Registrant and Alan Glicklich, dated January 26, 2022 (Filed With SEC on March 17, 2022)

Underwriting Agreement by and among Chinook Therapeutics, Inc. and SVB Leerink and Evercore ISI, as Representatives of the several underwriters, dated November 9, 2021 (Filed With SEC on November 10, 2021)

Form of Pre-Funded Warrant (Filed With SEC on November 10, 2021)

Sublease between the Registrant and Wireless Advocates LLC dated May 24, 2021 (Filed With SEC on August 12, 2021)

Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on April 7, 2021)

Form of Inducement Stock Option Agreement (Filed With SEC on April 7, 2021)

Contingent Value Rights Agreement, dated October 2, 2020, by and between Aduro Biotech, Inc. and Computershare Trust Company, N.A (Filed With SEC on November 5, 2020)

Sublease between the Registrant and Perfect Day, Inc., dated August 25, 2020 (Filed With SEC on November 5, 2020)

Form of Separation Agreement (Standard) (Filed With SEC on October 7, 2020)

Form of Separation Agreement (Stephen T. Isaacs) (Filed With SEC on October 7, 2020)

Form of Consulting Agreement (Filed With SEC on October 7, 2020)

Form of Indemnification Agreement (Filed With SEC on October 7, 2020)

Form of Employment Agreement (US) (Filed With SEC on October 7, 2020)

Form of Employment Agreement (Canada) (Filed With SEC on October 7, 2020)

Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated August 17, 2020, by and among Aduro Biotech, Inc., Aspire Merger Sub, Inc. and Chinook Therapeutics U.S.,... (Filed With SEC on August 18, 2020)

Note Termination Agreement, dated August 17, 2020, by and among Aduro Biotech, Inc., Chinook Therapeutics U.S., Inc. and certain investors named therein (Filed With SEC on August 18, 2020)

License Agreement, dated December 16, 2019, by and between Chinook Therapeutics U.S., Inc. and AbbVie Ireland Unlimited Company (Filed With SEC on July 22, 2020)

Amended and Restated Executive Employment Agreement by and between the Company and Stephen T. Isaacs, dated July 2, 2020 (Filed With SEC on July 2, 2020)

Amendment to the Aduro Biotech, Inc. Amended and Restated Severance Plan and Summary Plan Description (Filed With SEC on July 2, 2020)

Letter Agreement by and between the Company and Blaine Templeman, dated June 29, 2020 (Filed With SEC on July 2, 2020)

Agreement and Plan of Merger and Reorganization, dated June 1, 2020, by and among Aduro Biotech, Inc., Aspire Merger Sub, Inc. and Chinook Therapeutics U.S., Inc (Filed With SEC on June 2, 2020)

Note Purchase Agreement, dated as of June 1, 2020, by and among Chinook Therapeutics U.S., Inc. and certain investors named therein (Filed With SEC on June 2, 2020)

Form of Convertible Promissory Note (Filed With SEC on June 2, 2020)

Form of Support Agreement by and between Aduro Biotech, Inc. and certain stockholders of Chinook Therapeutics U.S., Inc (Filed With SEC on June 2, 2020)

Form of Support Agreement by and between Chinook Therapeutics U.S., Inc. and certain stockholders of Aduro Biotech, Inc (Filed With SEC on June 2, 2020)

Form of Lock-Up Agreement (Filed With SEC on June 2, 2020)

Form of CVR Agreement (Filed With SEC on June 2, 2020)

Consulting Agreement, dated as of June 1, 2020, by and between Aduro Biotech, Inc. and Andrea van Elsas, Ph.D (Filed With SEC on June 2, 2020)

Amendment No. 3 to Exclusive License Agreement between Aduro Biotech, Inc. and the Memorial Sloan Kettering Cancer Center, dated March 30, 2020 (Filed With SEC on May 4, 2020)

Termination Agreement between Andrea van Elsas and Aduro Biotech, Inc. dated April 10, 2020 (Filed With SEC on May 4, 2020)

Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 9, 2020)

Retention Bonus Agreement dated January 9, 2020, between the Company and Blaine Templeman (Filed With SEC on March 9, 2020)

Retention Bonus Agreement dated January 9, 2020, between the Company and Celeste Ferber (Filed With SEC on March 9, 2020)

Retention Bonus Agreement dated January 9, 2020, between the Company and Dimitry Nuyten (Filed With SEC on March 9, 2020)

Amendment No. 2 to Executive Employment Agreement dated January 13, 2020, between the Company and Stephen T. Isaacs (Filed With SEC on March 9, 2020)

Retention Bonus Agreement dated January 10, 2020, between the Company and Stephen T. Isaacs (Filed With SEC on March 9, 2020)

Consulting Agreement dated January 22, 2020, between the Company and Danforth Advisors, LLC (Filed With SEC on January 23, 2020)

Offer of Employment Letter of Interim Chief Financial Officer (Filed With SEC on August 1, 2019)

Offer of Employment Letter of Chief Medical Officer (Filed With SEC on August 1, 2019)

Aduro Biotech, Inc. Non-Employee Director Compensation Policy (Filed With SEC on May 7, 2019)

Amendment No. 1 to Sales Agreement between Aduro Biotech, Inc. and Cowen and Company, LLC, dated February 27, 2019 (Filed With SEC on February 27, 2019)

Research Collaboration and Exclusive License Agreement between Aduro Biotech, Inc. and Eli Lilly and Company, dated December 18, 2018 (Filed With SEC on February 27, 2019)

Non-Employee Director Compensation Policy (Filed With SEC on August 1, 2018)

Employment Agreement between Aduro Biotech Holdings, Europe B.V. and Mr. Andrea Van Elsas dated October 30, 2015 (Filed With SEC on March 1, 2018)

Addendum to Employment Agreement between Aduro Biotech Holdings, Europe B.V. and Mr. Andrea Van Elsas dated October 4, 2017 (Filed With SEC on March 1, 2018)

Confidential Separation Agreement and General Release between Aduro Biotech, Inc. and Dirk Brockstedt dated January 1, 2018 (Filed With SEC on March 1, 2018)

Confidential Separation Agreement and General Release between Aduro Biotech, Inc. and Gregory Schafer dated March 1, 2018 (Filed With SEC on March 1, 2018)

Common Stock Sales Agreement between Aduro Biotech, Inc. and Cowen and Company, LLC, dated August 2, 2017 (Filed With SEC on August 2, 2017)

Aduro Biotech, Inc. Non-Employee Director Compensation Policy Approved by the Board of Directors on March 30, 2015 As Amended on June 21, 2016 (Filed With SEC on May 2, 2017)

ADURO BIOTECH, INC. AMENDED AND RESTATED SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION Effective Date: December 9, 2016 (Filed With SEC on March 1, 2017)

AMENDMENT 1 TO EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on March 1, 2017)

SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on March 1, 2017)

ADURO BIOTECH, INC. AMENDED AND RESTATED SEVERANCE PLAN AND SUMMARY PLANDESCRIPTION Effective Date: December 9, 2016 ADURO BIOTECH, INC. AMENDED AND RESTATED SEVERANCE PLAN AND... (Filed With SEC on December 15, 2016)

ADURO BIOTECH, INC.626 Bancroft Way, 3C, Berkeley, CA ###-###-#### (Filed With SEC on November 2, 2016)

ADURO BIOTECH, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2015 EQUITY INCENTIVE PLAN) (Filed With SEC on September 14, 2016)

FIRST AMENDMENT TO LEASE (Filed With SEC on August 3, 2016)

ADURO BIOTECH, INC. $100,000,000 cOMMON STOCK SALES AGREEMENT (Filed With SEC on May 2, 2016)

AMENDMENT TO RESEARCH AND LICENSE AGREEMENTS (Filed With SEC on March 8, 2016)

SHARE SALE AGREEMENT Dated 24 September 2015 BETWEEN Brabant Life Sciences Seed Fonds B.V. Spin-Off Fonds Brabant B.V. BFF B.V. as the Sellers AND Aduro Biotech, Inc. as the... (Filed With SEC on November 23, 2015)

Exhibit 10.38 June 5, 2015 (Filed With SEC on August 11, 2015)

SEVERANCE AGREEMENT (Filed With SEC on April 14, 2015)

ADURO BIOTECH, INC. (a Delawarecorporation) [] Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on April 6, 2015)

ADURO BIOTECH, INC. 2015 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:MARCH 30, 2015 APPROVED BY THE STOCKHOLDERS:APRIL 1, 2015 IPO DATE/EFFECTIVE DATE:[ ], 2015 (Filed With SEC on April 6, 2015)

ADURO BIOTECH, INC. 2015 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE (Filed With SEC on April 6, 2015)

ADURO BIOTECH, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS:MARCH 30, 2015 APPROVED BY THE STOCKHOLDERS:APRIL 1, 2015 IPO DATE/EFFECTIVE DATE:[ ], 2015 (Filed With SEC on April 6, 2015)

ADURO BIOTECH, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY APPROVED BY THE BOARD OF DIRECTORS MARCH 30, 2015 (Filed With SEC on April 6, 2015)

COLLABORATION AND LICENSE AGREEMENT dated as of March 12, 2015 between ADURO BIOTECH, INC. and NOVARTISPHARMACEUTICALS CORPORATION TABLE OF CONTENTS (Filed With SEC on April 6, 2015)

ADUROBIOTECH, INC. SERIES E PREFERRED STOCK PURCHASE AGREEMENT (Filed With SEC on April 6, 2015)

ADUROBIOTECH, INC. COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on April 6, 2015)

ADURO BIOTECH, INC. AMENDED ANDRESTATED INVESTOR RIGHTS AGREEMENT December 19, 2014 TABLE OF CONTENTS (Filed With SEC on March 11, 2015)

ONCOLOGIC, INC. 2000LONG-TERM INCENTIVE PLAN ARTICLE 1. ESTABLISHMENT AND PURPOSE (Filed With SEC on March 11, 2015)

ONCOLOGIC, INC. 2000 LONG-TERM INCENTIVE PLAN SUMMARY OF STOCK OPTION GRANT (Filed With SEC on March 11, 2015)

TRITON BIOSYSTEMS, INC. 2001 EQUITY INCENTIVE PLAN (Filed With SEC on March 11, 2015)

NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE TRITONBIOSYSTEMS, INC. 2001 EQUITY INCENTIVE PLAN (Filed With SEC on March 11, 2015)

ADURO BIOTECH STOCKINCENTIVE PLAN (Filed With SEC on March 11, 2015)

ADURO BIOTECH STOCKINCENTIVE PLAN STOCK OPTION AGREEMENT (Filed With SEC on March 11, 2015)

INDEMNIFICATION AGREEMENT (Filed With SEC on March 11, 2015)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on March 11, 2015)

AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on March 11, 2015)

ADURO BIOTECH 626Bancroft Way, 3C, Berkeley, CA ###-###-#### PHONE ###-###-#### FAX ###-###-#### EMAIL ***@*** WEB www.adurobiotech.com (Filed With SEC on March 11, 2015)

SEVERANCE AGREEMENT (Filed With SEC on March 11, 2015)

ADURO BIOTECH 626 Bancroft Way, 3C, Berkeley, CA ###-###-#### PHONE ###-###-#### FAX ###-###-#### WEB www.adurobiotech.com (Filed With SEC on March 11, 2015)

SEVERANCE AGREEMENT (Filed With SEC on March 11, 2015)

CONFIDENTIAL RESEARCH AND LICENSE AGREEMENT between Janssen Biotech, Inc. and Aduro Biotech,Inc. May 27, 2014 (Filed With SEC on March 11, 2015)

CONFIDENTIAL GVAX PROSTATE LICENSE AGREEMENT between Janssen Biotech,Inc. and AduroBiotech, Inc. May 27, 2014 CONFIDENTIAL (Filed With SEC on March 11, 2015)

CONFIDENTIAL RESEARCH AND LICENSE AGREEMENT between Janssen Biotech, Inc. and Aduro Biotech,Inc. Executed as of October 13, 2014 CONFIDENTIAL (Filed With SEC on March 11, 2015)

EXCLUSIVE LICENSE AGREEMENT BETWEEN THE JOHNSHOPKINS UNIVERSITY & ADURO BIOTECH JHUAgreement: # -A19340 LICENSE AGREEMENT (Filed With SEC on March 11, 2015)

EXCLUSIVE LICENSE BETWEEN ADURO BIOTECHINC AND THEREGENTS OF THE UNIVERSITY OF CALIFORNIA FOR LISTERIA MONOCYTOGENES PHAGE INTEGRATION VECTOR (Filed With SEC on March 11, 2015)

ASSET PURCHASE AGREEMENT (Filed With SEC on March 11, 2015)

PATENT AND TECHNOLOGY LICENSE AND MATERIALS TRANSFER AGREEMENT BY AND BETWEEN THEJOHNS HOPKINS UNIVERSITY & ADURO BIOTECH, INC. JHU Agreement: # -A21083 PATENT AND TECHNOLOGY... (Filed With SEC on March 11, 2015)

RESTATED AND AMENDED LICENSE AGREEMENT (Filed With SEC on March 11, 2015)

LICENSE AGREEMENT (Filed With SEC on March 11, 2015)

EXCLUSIVE LICENSE BETWEEN ADURO BIOTECHINC AND THEREGENTS OF THE UNIVERSITY OF CALIFORNIA FOR CYCLIC-DI-NUCLEOTIDES THAT STIMULATE HUMAN STING VARIANTS AND STIMULATOR OFINTERFERON... (Filed With SEC on March 11, 2015)

EXCLUSIVE LICENSE AGREEMENT for INSTITUTIONS TECHNOLOGY Compositions & Methods for Altering Second Messenger Signaling Reference Numbers: Rutgers:L2015-0995_LFSC Rockefeller: RU... (Filed With SEC on March 11, 2015)

MANUFACTURING SERVICES AGREEMENT (Filed With SEC on March 11, 2015)

PROCESS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT (Filed With SEC on March 11, 2015)

BANCROFT WAY, LLC FourthAddendum to Office Lease (Filed With SEC on March 11, 2015)

AMENDMENT # 1 TO: THE EXCLUSIVELICENSE AGREEMENT BETWEEN ADURO BIOTECH INC. AND THE REGENTS FOR CYCLIC-DI-NUCLEOTIDES THAT STIMULATE HUMAN STING VARIANTS ANDSTIMULATOR OF... (Filed With SEC on March 11, 2015)

ADURO BIOTECH, INC. SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION Plan Effective Date: March 4, 2015 -1- ADURO BIOTECH, INC. SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION (Filed With SEC on March 11, 2015)

Category

Industry

Companies

Contracts

ADURO BIOTECH, INC. Contracts & Agreements